Emmanuel S. Antonarakis, Johns Hopkins, below .
Mentions 14 ongoing clinical trials, including this:
"Another approach that we have begun to test here at Johns Hopkins is the use of high-dose testosterone in patients with CRPC that has become resistant to abiraterone or enzalutamide (NCT02090114). Preclinical work has supported the idea that exposing CRPC cells to very high doses of testosterone can induce cell death by causing double-strand breaks in DNA as well as by preventing DNA relicensing during the cell cycle. The first of these studies, which was published by Schweizer and colleagues in Science Translational Medicine in 2015, found that monthly intramuscular injections of high-dose testosterone produced significant clinical responses in approximately half of the patients with CRPC. One of our emerging hypotheses is that high-dose testosterone therapy may also work by eliminating AR splice variants."